DrugDashboards

Gvoke PFS 1 mg Pre-filled Syringe

glucagon injection, solution · GLUCAGON 1 mg/.2mL · Injection, Solution · Subcutaneous · Xeris Pharmaceuticals, Inc.

NDC 72065-0131-12 · 2 POUCH in 1 CARTON / 1 SYRINGE, PLASTIC in 1 POUCH / .2 mL in 1 SYRINGE, PLASTIC · NDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $1606.19 per mL over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 72065-0131-11) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$1,620.84per unit
middle half $1,580.80–$1,713.82 · 3,013 plans · Apr 1, 2026
Est. net of rebatesⓘ
$972.50–$1,215.63
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
55%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 24%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1000.00$2000.00May 2020Sep 2026$1606.19
27 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$651.04
Reported to Texas DSHS · 2026 annual filing · Xeris Pharmaceuticals

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$818,706
1,361 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

40● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for glucagon injection, solution (injectable) in the next 90 days

sterile injectable · sole-source market · price up 3% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA212097
TE code
—
Approval date
Sep 10, 2019
Patents / exclusivity
9 patents, 0 exclusivities
TypeNumber / codeExpires
patent9649364Apr 22, 2036
patent9649364Apr 22, 2036
patent9649364Apr 22, 2036
patent9649364Apr 22, 2036
patent11590205Apr 22, 2036
patent11590205Apr 22, 2036
patent11590205Apr 22, 2036
patent11590205Apr 22, 2036
patent11590205Apr 22, 2036

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of glucagon injection, solution (Injection, Solution)

LabelerStrengthFirst seenLast seen
Xeris Pharmaceuticals, Inc.GLUCAGON .5 mg/.1mLJul 15, 2026Sep 2, 2026
Xeris Pharmaceuticals, Inc.GLUCAGON 1 mg/.2mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Gvoke PFS 1 mg Pre-filled Syringe — NDC 72065-0131-12," retrieved September 3, 2026, https://drugdashboards.com/drug/72065013112.

Free to cite with attribution — see how the data is put together.